BioCentury
ARTICLE | Clinical News

IAB2M: Phase I/IIa data

January 18, 2016 8:00 AM UTC

Data from 38 patients with progressive metastatic prostate cancer in an open-label, U.S. Phase I/IIa trial showed that a single IV infusion of IAB2M detected 83.9% of 410 bone lesions vs. 51% of lesio...